Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002030441 | SCV002274740 | likely pathogenic | Granulomatous disease, chronic, X-linked | 2021-02-01 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Gly408 amino acid residue in CYBB. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 29560547, 9585602, 10627478, 8634410). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CYBB protein function. This variant has not been reported in the literature in individuals with CYBB-related conditions. This variant is present in population databases (rs151344474, ExAC 0.01%). This sequence change replaces glycine with alanine at codon 408 of the CYBB protein (p.Gly408Ala). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and alanine. |